Cotadutide

What Is Cotadutide?

Cotadutide (MEDI0382) is an investigational dual GLP-1/glucagon receptor agonist developed by AstraZeneca. It belongs to the same dual agonist class as survodutide and pemvidutide, combining GLP-1-mediated appetite suppression with glucagon-driven energy expenditure and liver fat oxidation.

Cotadutide has been studied in Phase 2 trials for type 2 diabetes and MASH (metabolic dysfunction-associated steatohepatitis). The glucagon component's liver-specific effects make dual GLP-1/glucagon agonists particularly promising for MASH — a disease with no approved treatments and a massive unmet medical need.

Development has progressed more slowly than competitors (survodutide, pemvidutide), and AstraZeneca's strategic decisions regarding the program may evolve based on competitive landscape developments.

What The Research Says

Phase 2 data showed significant reductions in liver fat (up to 39% reduction) and weight loss in MASH patients. HbA1c improvements in diabetic populations were consistent with GLP-1 class effects.

The competitive landscape for dual GLP-1/glucagon agonists is increasingly crowded, with survodutide (Boehringer Ingelheim) further ahead in clinical development for MASH.

📚 Key Reference: PMID: 35353914 (cotadutide Phase 2)

Common Uses

• MASH/NASH (investigational)
• Type 2 diabetes (investigational)
• Obesity (investigational)

Important Safety Information

GI side effects typical of GLP-1 class. Liver function monitoring needed. Full safety characterization pending.

Questions To Ask Your Provider

1. How does cotadutide compare to survodutide?
2. What MASH-specific endpoints are being studied?

Regulatory Status

NOT FDA-approved. In Phase 2 clinical trials.